Health Canada Approves VENCLEXTA® in combination with azacitidine or low dose cytarabine for untreated Acute Myeloid Leukemia
Health Canada’s approval of VENCLEXTA for newly diagnosed AML patients who are ineligible for intensive chemotherapy is supported by data from two Phase 3 trials – VIALE-A and VIALE-C 1 . The VIALE-A trial demonstrated a statistically significant increase in overall survival with VENCLEXTA in combination with azacitidine compared to azacitidine alone. 1 In the VIALE-C trial, clinical benefit was based on rate and … Health Canada’s approval of VENCLEXTA for newly diagnosed AML patients who are ineligible for intensive chemotherapy is supported by data from two Phase 3 trials – VIA...
Source: investingnews.com